CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print May 23, 2008
CA Cancer J Clin 2008
doi: 10.3322/CA.2008.0002
© 2008 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Freely available CME: Take the course for this article:
Management of Complications of Prostate Cancer Treatment
Right arrow All Versions of this Article:
CA.2008.0002v1
58/4/196    most recent
Right arrow Submit a letter to the editor
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Michaelson, M. D.
Right arrow Articles by Smith, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michaelson, M. D.
Right arrow Articles by Smith, M. R.

Management of Complications of Prostate Cancer Treatment

M. Dror Michaelson, MD, PhD*, Shane E. Cotter, MD, PhD*, Patricio C. Gargollo, MD*, Anthony L. Zietman, MD, Douglas M. Dahl, MD and Matthew R. Smith, MD, PhD

Dr. Michaelson is Assistant Professor of Medicine, Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA.
Dr. Cotter is Resident, Harvard Radiation Oncology Program, Boston, MA.
Dr. Gargollo is Instructor in Surgery, Harvard Medical School, Department of Urology, Massachusetts General Hospital, Boston, MA.
Dr. Zietman is Professor of Radiation Oncology, Jenot and William Shipley, Harvard Medical School, Massachusetts General Hospital, Boston, MA.
Dr. Dahl is Associate in Urology, Massachusetts General Hospital; and Assistant Professor of Surgery (Urology), Harvard Medical School, Boston, MA.
Dr. Smith is Associate Professor of Medicine; and Director of Genitourinary Medical Oncology, Massachusetts General Hospital, Boston, MA.

    ABSTRACT

Prostate cancer is the most commonly diagnosed noncutaneous cancer in men in the United States. Treatment of men with prostate cancer commonly involves surgical, radiation, or hormone therapy. Most men with prostate cancer live for many years after diagnosis and may never suffer morbidity or mortality attributable to prostate cancer. The short-term and long-term adverse consequences of therapy are, therefore, of great importance. Adverse effects of radical prostatectomy include immediate postoperative complications and long-term urinary and sexual complications. External beam or interstitial radiation therapy in men with localized prostate cancer may lead to urinary, gastrointestinal, and sexual complications. Improvements in surgical and radiation techniques have reduced the incidence of many of these complications. Hormone treatment typically consists of androgen deprivation therapy, and consequences of such therapy may include vasomotor flushing, anemia, and bone density loss. Numerous clinical trials have studied the role of bone antiresorptive therapy for prevention of bone density loss and fractures. Other long-term consequences of androgen deprivation therapy may include adverse body composition changes and increased risk of insulin resistance, diabetes, and cardiovascular disease. Ongoing and planned clinical trials will continue to address strategies to prevent treatment-related side effects and improve quality of life for men with prostate cancer.




eLetters:

Read all eLetters

Interstitial Brachytherapy
Paul Herstein, MD, et al.
CA Online, 2 Sep 2008 [Full text]
Reply to Herstein et al.
Ted Gansler, MD, MBA
CA Online, 2 Sep 2008 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH
Copyright © 2008 by American Cancer Society.